ANTHEMNSEAnthem Biosciences Limited· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Fri, 22 May, 2026 · 15:49 IST

Anthem Biosciences Limited has informed the Exchange about Transcript

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.7%Reaction day
₹775.85
prior close
₹777.10
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.8%-2.6% vs market
Pharmaceuticals & Biotechnology peers, median of 169sector · industry level+0.8%-2.5% vs sector

On the reaction day the stock moved 2.6 pts less than Nifty Midcap 150 and 2.5 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.8
10m
+0.8
15m
+0.6
30m
+0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.7+0.8-2.6+0.8-2.5
Next day
-0.7+1.3-2.0+1.4-2.1
2d
-2.5+1.7-4.2+1.5-4.0
3d
-3.1+0.3-3.4+0.8-3.9
4d
-3.3-1.1-2.3+0.5-3.8
5d
-2.9-0.9-2.1+1.0-3.9
1w
-4.0-0.8-3.1+0.4-4.4
15d
-1.5+0.7-2.3+1.1-2.6
1m
-1.9+1.1-3.0+3.4-5.3
2m
+1.7+1.9-0.2+5.5-3.8
3m
+12.8+4.6+8.2+8.2+4.6
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 169Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported FY26 consolidated revenue of Rs. 2,124 crore (up 18% YoY), with CRDMO contributing Rs. 1,773 crore (83% of revenue, 18% growth) and specialty ingredients Rs. 352 crore. EBITDA was Rs. 990 crore with 43.4% margins (up 420 bps), and PAT was Rs. 592 crore (26% margins, up 31% YoY). Q4 FY26 was the highest-ever revenue quarter at Rs. 611 crore with 48.1% EBITDA margins. Net cash position is Rs. 1,375 crore. Management flagged that destocking headwinds from FY26 are now largely behind them with restocking underway, and GLP-1 represents a significant future opportunity for import substitution in India. Unit 4 expansion (Phase 1: Rs. 1,200 crore over FY27–FY28) will double custom synthesis capacity to ~790 kiloliters. Commercial portfolio grew to 14 molecules (4 new in FY26), with 10 Phase 3 programs and 100+ early-stage programs ongoing. Management refrained from giving formal FY27 guidance but aspires to maintain ~20% historical revenue growth trajectory.

Likely market impact

Strong profitability expansion (EBITDA margins crossed 43%) with cash-rich balance sheet positions Anthem well for its large Unit 4 capex cycle. The destocking cycle appearing over and a growing Phase 3 pipeline (10 molecules, all from emerging biotech) provide visibility into sustained growth, though the lack of formal near-term guidance may limit near-term re-rating.